Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, comments on the need to find biomarkers to identify patients with high-risk smoldering myeloma early in order to initiate treatment and prevent disease progression. In addition, Prof. Davies explains that it is important to learn to better use current treatments in order to minimize side effects in these patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.